More than 40% of people with inflammatory bowel disease have made significant financial trade-offs to afford the health care ...

Across the Western world, the prevalence of these chronic and serious conditions, which have no cure, is rising. In Denmark alone, 50,000 people suffer from either Crohn's disease or ulcerative ...

This type of digestive upset can initially seem like a milder form of colic. But colitis requires prompt and appropriate ...

An anti-TL1A monoclonal antibody called tulisokibart may help people with moderate to severe ulcerative colitis achieve ...

Being away when you have an unpredictable condition can be challenging. These go-tos make trains, planes, and automobiles far ...

The results showed that 26% of patients who received tulisokibart achieved clinical remission at week 12 compared with 1% of ...

Ulcerative colitis is a chronic inflammatory bowel disease that can flare up unexpectedly. Sometimes the symptoms can be life threatening, and it’s crucial to know how to manage an emergency ...

Champions for a Cure will raise funds and awareness for Crohn's and Colitis on Oct. 25 ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Johnson & Johnson (JNJ) announced Thursday TREMFYA (guselkumab) data in both Crohn's disease (CD) and ulcerative colitis (UC) showing ...

Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA)–The ...

Spherix Global Insights said AbbVie’s Skyrizi has quickly blasted past Eli Lilly’s Omvoh in ulcerative colitis, ...